About this Research Topic
The field of cancer research is a vast and complex one, with the disease being the second leading cause of morbidity and death worldwide. The clinical impact of cancer is often measured in terms of risk of recurrence, probability of remission, and survival rates. One key factor in suppressing tumor initiation and modulating tumor immunogenicity is genome integrity, which is promoted by various DNA repair pathways. However, despite significant progress in treatment approaches such as DNA repair targeted therapy, chemotherapy, and immunotherapy, outcomes are often limited due to low response rates and resistance to these treatments, often associated with low immunogenicity of the tumor microenvironment.
The primary aim of this research topic is to explore the DNA repair defect and metabolic demand of cancer cells, and their implications for tumor immunogenicity and immune-based therapy. This includes investigating the crossroads of cancer cells' innate immune signaling, novel DNA repair targeted treatment approaches to enhance immunotherapy, and how DNA repair aberration in cancer cells influences cancer cell-intrinsic immune signaling and immune phenotypes. The goal is to decode cancer cell metabolism to enhance DNA damage associated genetic vulnerability, thereby enhancing the efficacy of targeted therapy and immunotherapy.
The scope of this research topic is focused on the exploration of DNA repair defects and metabolic vulnerability of cancer cells. We welcome articles addressing, but not limited to, the following themes: examining the crossroad of cancer cells' innate immune signaling, novel DNA repair targeted treatment approaches to enhance immunotherapy, how DNA repair aberration in cancer cells influence cancer cell-intrinsic immune signaling and immune phenotypes, and whether the cancer cells' intrinsic innate immune signaling factors are critical for innate immune cell inflammatory signaling activation.
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
The primary aim of this research topic is to explore the DNA repair defect and metabolic demand of cancer cells, and their implications for tumor immunogenicity and immune-based therapy. This includes investigating the crossroads of cancer cells' innate immune signaling, novel DNA repair targeted treatment approaches to enhance immunotherapy, and how DNA repair aberration in cancer cells influences cancer cell-intrinsic immune signaling and immune phenotypes. The goal is to decode cancer cell metabolism to enhance DNA damage associated genetic vulnerability, thereby enhancing the efficacy of targeted therapy and immunotherapy.
The scope of this research topic is focused on the exploration of DNA repair defects and metabolic vulnerability of cancer cells. We welcome articles addressing, but not limited to, the following themes: examining the crossroad of cancer cells' innate immune signaling, novel DNA repair targeted treatment approaches to enhance immunotherapy, how DNA repair aberration in cancer cells influence cancer cell-intrinsic immune signaling and immune phenotypes, and whether the cancer cells' intrinsic innate immune signaling factors are critical for innate immune cell inflammatory signaling activation.
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
Keywords: metabolism, immunotherapy, cancer, oncology, DNA damage
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
